for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AstraZeneca plc

AZN.L

Latest Trade

8,699.00GBp

Change

249.00(+2.95%)

Volume

1,610,209

Today's Range

8,412.00

 - 

8,736.00

52 Week Range

5,871.00

 - 

10,120.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
8,450.00
Open
8,467.00
Volume
1,610,209
3M AVG Volume
42.87
Today's High
8,736.00
Today's Low
8,412.00
52 Week High
10,120.00
52 Week Low
5,871.00
Shares Out (MIL)
1,312.28
Market Cap (MIL)
111,074.50
Forward P/E
27.34
Dividend (Yield %)
2.56

Next Event

Dividend For AZN.L - 69.6000 GBX

Latest Developments

More

Redx Pharma Signs Out Licensing Agreement With AstraZeneca

Astrazeneca Plc Prices $3 Bln Bond Issue

Wockhardt Intends To Supply 30 Mln Fill-&-Finish COVID-19 Vaccine Doses To AstraZeneca

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About AstraZeneca plc

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Industry

Biotechnology & Drugs

Contact Info

1 Francis Crick Avenue

CB2 0AA

United Kingdom

+44.20.73045000

https://www.astrazeneca.com/Home

Executive Leadership

Leif Johansson

Independent Non-Executive Chairman of the Board

Pascal Soriot

Chief Executive Officer, Executive Director

Marc Dunoyer

Chief Financial Officer, Executive Director

Katarina Ageborg

Executive Vice President - Sustainability, Chief Compliance Officer

Fiona Cicconi

Executive Vice President - Human Resources

Key Stats

2.30 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.5K

2018

22.1K

2019

24.4K

2020(E)

26.6K
EPS (USD)

2017

4.280

2018

3.460

2019

3.500

2020(E)

4.030
Price To Earnings (TTM)
67.50
Price To Sales (TTM)
5.64
Price To Book (MRQ)
11.84
Price To Cash Flow (TTM)
24.83
Total Debt To Equity (MRQ)
161.37
LT Debt To Equity (MRQ)
127.60
Return on Investment (TTM)
4.83
Return on Equity (TTM)
3.36

Latest News

Latest News

Argentina and Mexico to produce AstraZeneca COVID-19 vaccine

Argentina and Mexico will produce the AstraZeneca COVID-19 vaccine for most of Latin America, Argentine President Alberto Fernandez said on Wednesday after a meeting with company executives involved in the project.

Brazilian billionaire Lemann leads initiative to build COVID-19 vaccine factory

Brazilian billionaire Jorge Lemann's foundation and other business interests will fund the building of factory to produce the COVID-19 vaccine being developed by Oxford University and pharmaceutical company AstraZeneca PLC <AZN.L>.

London stocks gain on week; U.S. jobs data, tensions with China weigh

London's FTSE 100 closed flat on Friday as a commodity-linked slump offset gains spurred by some upbeat earnings and AstraZeneca, while an index of more domestically-focused stocks rose as hopes grew of a trade deal with the European Union.

Japan in deals with AstraZeneca, Novavax for COVID-19 vaccines

Japan plans to buy AstraZeneca Plc's experimental COVID-19 vaccine and fund a local company to manufacture Novavax's vaccine candidate, ramping up its stockpile plan as it battles surging infections.

AstraZeneca to supply Japan with COVID-19 vaccine thru JCR Pharma output, imports

AstraZeneca said on Friday JCR Pharma will help make a portion of its potential COVID-19 vaccine in Japan and it will import shots as part of its deal to supply the Asian nation with up 120 million doses from early 2021.

Japan says in deal to purchase AstraZeneca's COVID-10 vaccine

Japan has agreed to acquire 120 million doses of AstraZeneca Plc's experimental COVID-19 vaccine if it is successfully developed, the health minister said on Friday.

Japan to agree supply deal soon for AstraZeneca's coronavirus vaccine - Kyodo

The Japanese government will soon agree a supply deal for more than 100 million doses of a coronavirus vaccine being developed by AstraZeneca Plc <AZN.L>, Kyodo news agency reported on Friday.

Factbox: AstraZeneca's potential coronavirus vaccine

AstraZeneca signed its first COVID-19 vaccine supply deal with a Chinese company, Kangtai Bio, on Thursday, opening up distribution to one of the world's most populous countries.

AstraZeneca in first COVID-19 vaccine deal with Chinese company

Shenzhen Kangtai Biological Products will produce AstraZeneca Plc's potential COVID-19 vaccine in mainland China, the British drugmaker said on Thursday, its first deal to supply one of the world's most populous countries.

AstraZeneca in deal with Kangtai Bio to supply potential COVID-19 vaccine in China

AstraZeneca PLC has signed an exclusive framework agreement with China's Shenzhen Kangtai Biological Products to supply its COVID-19 vaccine candidate in mainland China, the British pharmaceutical giant said on Thursday.

India's Wockhardt strikes deal to supply COVID-19 vaccines to UK

Indian drugmaker Wockhardt Ltd will supply millions of doses of multiple COVID-19 vaccines, including that being developed by AstraZeneca and Oxford University, under a deal with the UK government announced on Monday.

AstraZeneca to be exempt from coronavirus vaccine liability claims in most countries

AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries with which it has struck supply agreements, a senior executive told Reuters.

'So far, so good' on leading COVID vaccine, says AstraZeneca

Britain's AstraZeneca <AZN.L> said on Thursday that good data was coming in so far on its vaccine for COVID-19, already in large-scale human trials and widely seen as the front-runner in the race for a shot against the novel coronavirus.

AstraZeneca to be exempted from coronavirus vaccine liability claims in most countries

AstraZeneca has been granted protection from future product liability claims related to its COVID-19 vaccine hopeful by most of the countries it has so far struck supply agreements with, a senior executive told Reuters.

BRIEF-AstraZeneca Not Hit By U.S.-China Tensions Over Pandemic - Media Call

* ASTRAZENECA SAYS NEW LAUNCHES FOR CALQUENCE AND ENHERTU ARE SHOWING GOOD PROGRESS - MEDIA CALL

Lloyds Bank loss hits FTSE 100, AstraZeneca gains

Gloomy quarterly results from Lloyds Bank and a clutch of other companies led the FTSE 100 lower on Thursday, while AstraZeneca rose after topping analysts' expectations on the back of strong drug sales during coronavirus-driven lockdowns.

AstraZeneca tops forecasts on strong drug sales, outlook unchanged

Drugmaker AstraZeneca topped second-quarter sales and profit expectations on Thursday and stood by its 2020 forecasts, helped by strong sales in lockdowns of a diverse line-up, which now includes a potential coronavirus vaccine.

AstraZeneca diabetes drug shows promise in severe kidney condition

AstraZeneca's <AZN.L> diabetes treatment has shown promise in a late-stage trial to help to slow chronic kidney disease, putting it on track for possible expanded approvals ahead of rival drugs.

AstraZeneca's lung disease treatment gets FDA nod

The U.S. Food and Drug Administration approved AstraZeneca's drug to treat patients with a form of lung disease, the British drugmaker said on Friday.

Factbox: AstraZeneca's potential coronavirus vaccine

AstraZeneca's <AZN.L> experimental COVID-19 vaccine was safe and produced an immune response in early-stage clinical trials in healthy volunteers, data showed on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up